27 results about "Gluconeogenesis" patented technology

The invention relates to pediococcus acidilactici XZ106, which is classified and named as pediococcus acidilactici, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.30094, the preservation date is March 22, 2024, and the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The pediococcus acidilactici XZ106 can (1) relieve insulin resistance, regulate insulin and glucagon secretion and improve liver gluconeogenesis, so that diabetes hyperglycemia is improved; (2) weight gain, fat accumulation and liver lipid accumulation of obese mice are inhibited, glycolipid metabolism disorder of the mice is improved, and the composition has excellent effects of reducing fat and relieving obesity; (3) the level of IL-10 can be remarkably improved, and the anti-inflammatory ability of mice is improved; (4) vascular injury is reduced, so that diabetic complications and various cardiovascular diseases of atherosclerosis are prevented.

The invention discloses an FAM20B protein and application of an FAM20B protein inhibitor in prevention or treatment of glucolipid metabolism related diseases. Specifically, the invention discloses an application of an FAM20B protein and / or an FAM20B gene in regulation and control of liver glycolipid metabolism. The invention also discloses application of the FAM20B inhibitor in improving, preventing or treating liver glycolipid metabolism disorder or glycolipid metabolism related diseases (such as diabetes, metabolism related fatty liver disease MAFLD, obesity and the like). Experiments show that the FAM20B inhibitor can reduce the liver gluconeogenesis level, relieve impairment of glucose tolerance, relieve hyperglycemia of diabetic patients, reduce the fat content of the whole body and the liver, relieve liver lipid deposition, promote energy consumption, reduce food intake, promote fat burning and reduce liver fat accumulation; the compound can be used for preparing medicines for preventing and treating glucose and lipid metabolism disorder or glucose and lipid metabolism related diseases, and has a wide application prospect in the fields of prevention and treatment of metabolism related diseases.

The invention discloses application of thiamine in preparation of a product for treating subclinical ketosis of dairy cows, and belongs to the field of biological medicines. Tests prove that compared with dairy cows suffering from subclinical ketosis (SCK), by adding thiamine, the content of beta-hydroxybutyric acid (BHBA), the number of bacteria in milk and the number of somatic cells can be remarkably reduced, and the milk yield, the milk fat content, the acetic acid content and the A / P ratio are remarkably increased; the microbial diversity of rumen and excrement of the dairy cow can be adjusted; a metabonomics result shows that metabolite up-regulated after the thiamine is added mainly focuses on pyruvic acid metabolism, glycolysis or gluconeogenesis, tyrosine metabolism, glycerophospholipid metabolism and biosynthetic pathways of phenylalanine, tyrosine and tryptophan. The conclusion is that when thiamine is added into the SCK dairy cow, synthesis and catabolism of BHBA of an organism can be effectively regulated and controlled by adjusting the content of succinyl-coenzyme A, then subclinical ketosis is relieved, rumen fermentation is promoted, and therefore the milk yield and the milk quality are improved.

The application discloses a chrysanthemum stem and leaf active extract with improved fish heavy metal poisoning and a preparation method thereof. The chrysanthemum stem and leaf active extract is compounded by a chrysanthemum stem and leaf crude polysaccharide part and a chrysanthemum stem and leaf phenolic ketone part. The pharmacodynamic experiment results show that the chrysanthemum stem and leaf active extract has a good improvement effect on fish heavy metal poisoning. The chrysanthemum stem and leaf active extract can not only improve pathological changes such as heart and liver granuloma, kidney tubular cast, intestinal cavity expansion and gill lamella shedding caused by heavy metal poisoning, but also improve metabolic dysfunction such as taurine and hypotaurine metabolic disorder, pyruvic acid metabolic abnormality, tricarboxylic acid cycle disorder, glycolysis and gluconeogenesis disorder caused by heavy metal poisoning. The preparation method has reasonable whole preparation process design, can realize waste utilization, extends a chrysanthemum industry chain, expands a chrysanthemum resource utilization approach, is helpful to quality improvement and efficiency increase and green development of the chrysanthemum industry, and provides support for prevention and treatment of heavy metal poisoning.

The present application provides a soluble dietary fiber composition, its preparation method and application. After the soluble dietary fiber composition enters the colon, the ester bond in the alanine modified pectin is rapidly degraded, part of the chlorogenic acid is released, the secretion of anorectic hormone is stimulated, the appetite is reduced, and the heat intake is reduced; the remaining amide bond network is slowly degraded, realizing the slow and continuous release of chlorogenic acid. Lutein removes free radicals generated by fat decomposition, reducing the oxidative damage of L cells. Galactomannan and alanine modified pectin-glucan modified protein-chlorogenic acid ternary complex synergize to improve the molar ratio of butyric acid / propionic acid: propionic acid enhances satiety through intestinal gluconeogenesis, and butyric acid stimulates the secretion of GLP-1 / PYY, realizing endogenous appetite suppression. Galactomannan absorbs water to form a lubricating gel, softening the stool and increasing the stool volume; the ternary complex degrades to produce short-chain fatty acids, optimizing the intestinal microenvironment and enhancing gastrointestinal peristalsis, both of which synergistically improve constipation.

This invention relates to the field of feed additive technology, specifically to a compound plant-seaweed feed additive for reducing methane emissions in ruminants and its preparation method. It comprises the following raw materials in parts by weight: 40-60 parts sorghum husk powder, 30-50 parts purple sweet potato powder, 0.5-5 parts functional additives, 5-10 parts red algae, 5-10 parts brown algae, 5-12 parts *Lactobacillus plantarum*, 3-8 parts chitosan, 2-6 parts essential oil, 2-5 parts 3-nitrooxypropanol, 10-15 parts *Scutellaria baicalensis*, 8-12 parts *Codonopsis pilosula*, 3-8 parts *Isatis indigotica*, and 5-18 parts modified zeolite. Through the regulation of *Lactobacillus plantarum* and chitosan, the energy originally used to generate methane is converted into propionic acid. Propionic acid is a major gluconeogenic precursor in ruminants, which is directly converted into glucose for milk production or muscle growth.

The invention discloses application of thiamine in improving the sugar utilization rate and growth performance of sturgeons, and belongs to the field of aquaculture. It is proved for the first time that by enhancing a glycolytic pathway, inhibiting a gluconeogenesis pathway and promoting glycogen decomposition, the thiamine effectively improves the sugar metabolism capacity of sturgeons and reduces hepatic glycogen deposition and fat accumulation, so that the risk of metabolic disorder is reduced. Meanwhile, thiamine also promotes muscle fiber growth, so that the growth speed of the sturgeons and the feed utilization rate are remarkably increased. Therefore, the thiamine can be used as a feed additive for preparing the feed for improving the sugar utilization rate and the growth performance of the sturgeons. A safe and efficient nutrition regulation and control scheme is provided for sturgeon culture, the feed utilization rate and culture benefits are improved, meanwhile, ecological risks such as antibiotic abuse are avoided, and remarkable economic benefits and application prospects are achieved.

The application discloses application of a novel polypeptide in treatment or prevention of insulin resistance. The amino acid sequence of the polypeptide is shown in SEQ ID NO:1; or contains the sequence shown in SEQ ID NO:1; or a polypeptide derivative with deletion, insertion or substitution of one or more amino acids and with the same biological function as the polypeptide molecule. The polypeptide has the use in preparation of medicines for preventing and / or treating insulin resistance, lowering blood sugar level, stimulating glycogen synthesis and inhibiting gluconeogenesis.

The invention belongs to the technical field of biological medicine, and particularly relates to application of a liver sympathetic nerve activation inhibitor or liver sympathetic denervation in inhibiting abnormal liver glycometabolism. Phosphorylation of sympathetic IRS-1 is removed from the liver, downstream PI3K / AKT signal channels are cascaded, PI3K and AKT are phosphorylated, and insulin signal transduction is promoted. By means of nerve and up-regulation sympathetic nerve innervation, an IRS-1 / PI3K / AKT signal channel can be activated, liver insulin sensitivity can be improved, liver gluconeogenesis is inhibited by mediating an AKT / FOXO1 channel, and liver glycogen synthesis is promoted by mediating an AKT / GSK-3beta channel. Liver sympathetic denervation regulates and controls glucose metabolism by activating IRS-1 / PI3K / AKT signal channels, and it is prompted that inhibition of sympathetic nerve activity or cutting off of sympathetic nerve fibers may be a treatment target of related metabolic diseases.

A method for controlling blood sugar, including administering an effective amount of Gallocatechin Gallate (GCG) and Isoquercitrin (IQC) to a subject in need thereof is disclosed. In an aspect, a composition including a complex component of Gallocatechin Gallate and Isoquercitrin can effectively inhibit gluconeogenesis in liver cells and effectively improve transport of glucose in differentiated fat cells and liver cells, thereby exhibiting excellent blood sugar control efficacy.

A magnetic resonance imaging method for analyzing metabolic processes in a biological object that belong to glycolysis and / or gluconeogenesis is described for analyzing metabolic processes comprising the steps of generating a static magnetic field in a measurement space (2), defining one or more types of target molecules, each target molecule being selected from the group of metabolic substrates of the process of gluconeogenesis and glycolysis and having at least one phosphorus 31P bound in the target molecule itself, saturating the phosphorus 31P bound in the target molecules, exciting the nuclear spins of the phosphorus 31P atoms, acquiring nuclear magnetic resonance response signals belonging to endogenous phosphorylated molecules containing phosphorus in exchange with the saturated phosphorus 31P of the target molecules and determining from the response signals, a respective saturation transfer value from the phosphorus 31P of the target molecules to the endogenous phosphorylated molecules. The concentration of the phosphorus 31P bound in the target molecules is less than 500 pM and / or a nuclear magnetic resonance signal of the phosphorus 31P, bound in the target molecules, is below the signal-to-noise ratio referred to a measurement in a static magnetic field of 7T or less than 7T.

The present application relates to the field of biomedical technology, in particular to a prognostic marker of hepatocellular carcinoma patients, application of the prognostic marker, a prognosis prediction model and a prognosis evaluation device. The present application analyzes the transcriptome data of 374 hepatocellular carcinoma patients from the TCGA database, and verifies in samples from the ICGC database. After database screening, 7 hub genes (i.e. the prognostic marker described in the present application) are screened from 117 gluconeogenesis-related genes from gluconeogenesis metabolism, and a prognosis prediction model and a prognosis evaluation device are established using the prognostic marker, which provides a new guide for the molecular heterogeneity of hepatocellular carcinoma. The prognostic marker provided by the present application has important clinical significance, and the prognosis of hepatocellular carcinoma patients can be evaluated using the prognostic marker, and patients with poor prognosis can be identified, which provides a basis for precise treatment of patients.

The invention discloses an application of an endogenous metabolite micromolecule GGOH in preparation of liver cancer drugs, the structural formula of GGOH is as shown in formula (I): GGOH can be spontaneously converted into GGPP after entering the liver, and the GGOH can specifically up-regulate gluconeogenesis in the liver and reduce glycolysis level, so that the glucose metabolism steady state of the liver is improved, and the occurrence and development of fatty liver diseases are inhibited. The invention discloses the application of the endogenous metabolite micromolecule GGOH in preparing the fatty liver disease medicine or treating the liver cancer for the first time, clarifies the key regulation effect of the GGOH / GGPP level in the occurrence and development of the fatty liver disease, opens up a new direction for treating the fatty liver disease related to metabolic disorder, and has important scientific significance and clinical application prospects.

Provided herein are hepatic glucose production (HGP) assay methods which measure changes in total HGP, HGP due to glycogenolysis, and / or HGP due to gluconeogenesis, in response to a compound. Also provided herein are HGP assay methods which identify hepatic cells that are responsive to compounds by measuring changes in total HGP, HGP due to glycogenolysis, and / or HGP due to gluconeogenesis. Further provided herein are kits of reagents suitable for preparation of samples for in vitro measurement of HGP.

The application discloses a kind of flavonoids with the synergistic effect of reducing sugar and its preparation method and application, belong to functional food and microbial technology field.The synbiotic comprises plant lactobacillus N107 live bacteria and rhizoma polygonati polysaccharide ferment, and the ferment is prepared from the crude polysaccharide of raw rhizoma polygonati fermented by homologous bacteria under optimized conditions.After fermentation, the molecular weight of polysaccharide is reduced by more than 70%, the reducing sugar is significantly improved, and butyric acid is produced.In vitro hypoglycemic activity analysis shows that the synbiotic can significantly inhibit alpha-glucosidase activity;Cell experiment shows that it can significantly improve the glucose uptake rate of insulin-resistant HepG2 cells;Mechanically, it inhibits gluconeogenesis and promotes Glut4 translocation through PI3K / Akt / FoxO1 pathway.The present application directly uses raw rhizoma polygonati polysaccharide, avoids degradation by cooking, realizes green biotransformation of polysaccharide and synergistic hypoglycemic effect of synbiotic, has the advantages of probiotics and prebiotics, and the polysaccharide utilization rate is high.

The present invention discloses an application of Chlamydomonas reinhardtii red algae. The Chlamydomonas reinhardtii red algae of the present invention can significantly reduce fasting blood sugar, body weight, triglycerides and low-density lipoprotein cholesterol, and also enhance oral glucose tolerance and insulin sensitivity. In pathological analysis, Chlamydomonas reinhardtii red algae significantly improved lipid deposition and liver tissue damage. Mechanistically, Chlamydomonas reinhardtii red algae can significantly reduce the expression of G‑6‑Pase and PEPCK proteins, regulate the SOCS2 / JAK2 / STAT5 signaling pathway, and improve gluconeogenesis.

Provided is use of scavenger receptor class A member 3 or a reagent increasing the expression of scavenger receptor class A member 3 in preparing a hypoglycemic product. By means of overexpressing a human-derived SR-A3 gene in hamsters, it was found that the overexpression of the human-derived SR-A3 gene can reduce the plasma glucose concentration, decrease the plasma insulin concentration, improve glucose tolerance, enhance insulin sensitivity, reduce insulin resistance, lower the expression of gluconeogenesis-related genes, and inhibit the activation of the AKT signaling pathway. The present application provides a new target and a new strategy for the precise treatment of patients with hyperglycemia.

The invention relates to carbon quantum dots based on taurine and glucose and application of the carbon quantum dots in preparation of synergistic hypoglycemic drugs. The carbon quantum dot is prepared from glucose and taurine according to the molar ratio of 1: 10-10: 10 through a hydrothermal method, the particle size is 2-10 nm, and the carbon quantum dot has a graphitized lattice structure. The carbon quantum dot has high-efficiency scavenging capacity on hydroxyl free radicals and nitrogen free radicals. A zebra fish model experiment proves that the carbon quantum dot inhibits a gluconeogenesis process by inhibiting glucagon gene expression, remarkably reduces pancreatic cell apoptosis induced by high glucose, reduces an oxidative stress level, and realizes efficient blood glucose reduction through cooperation of multiple mechanisms. Compared with a taurine monomer, the carbon quantum dot has the advantages that the cardiac toxicity is obviously reduced under the same concentration, and the safety problem of high-dose use of taurine is solved. The preparation method disclosed by the invention is simple and low in cost, and the obtained carbon quantum dots have the characteristics of efficient blood glucose reduction and high safety, and can be used for preparing medicines for treating type 2 diabetes mellitus.

The invention discloses a feed additive for relieving liver glycogen accumulation of micropterus salmoides and application of the feed additive. The feed additive comprises a compound plant extract and an amino acid mixture, the part ratio of the composite plant extract to the amino acid mixture is (22-27): (50-60); the composite plant extract is prepared from curcumin, resveratrol, chicoric acid, berberine, quercetin, licoflavone, astragalus polysaccharide, zanthoxylin and danshinone; the amino acid mixture is prepared from L-arginine, L-leucine, L-lysine and L-alanine. Preferably, the feed additive also comprises 18-22 parts of coated short-chain fatty acid salt. The components of the feed additive can jointly activate insulin signal channels of the micropterus salmoides, promote glycolysis, inhibit gluconeogenesis, relieve insulin resistance induced by high glucose and reduce liver glycogen accumulation of the micropterus salmoides.

In the present specification, disclosed is a method for preparing a gallocatechin gallate (Gallocatable Gallate), which comprises the steps of: preparing a gallocatechin gallate (Gallocatable Gallate; the invention relates to application of a composition for regulating blood sugar or keeping healthy blood sugar values, in particular to application of a composition for regulating blood sugar or keeping healthy blood sugar values, such as GCG and isoquercitrin (IQC) and application of the composition to preparation of a composition for regulating blood sugar or keeping healthy blood sugar values. In one aspect, the composition of the present invention comprises a complex component of gallocatechin gallate and isoquercitrin, can effectively inhibit gluconeogenesis in hepatocytes, and can effectively improve glucose delivery in differentiated adipocytes and muscle cells, thus exhibiting excellent blood glucose regulation efficacy.

The invention discloses a composition with multiple hypoglycemic mechanisms. The composition comprises a membrane separation balsam pear polysaccharide extract, a membrane separation balsam pear saponin extract, a mulberry leaf extract, a momordica grosvenori extract and inulin, the membrane separation balsam pear polysaccharide extract and the membrane separation balsam pear saponin extract have an inhibition effect on the key enzyme fructose-1, 6-diphosphatase in the gluconeogenesis path; the mulberry leaf extract and the inulin have an inhibition effect on a key enzyme alpha-glucosidase in a sugar absorption path; the momordica grosvenori extract and the inulin enhance the insulin sensitivity; the invention further discloses a preparation method of the composition with the multiple hypoglycemic mechanisms. According to the invention, through synergistic interaction of triple pathways for inhibiting gluconeogenesis, inhibiting sugar absorption and improving insulin sensitivity, a dual hypoglycemic mechanism of'blocking endogenous sugar generation from a source and inhibiting exogenous sugar absorption from a terminal 'is formed, and the hypoglycemic efficiency is obviously improved compared with that of a single mechanism formula.

The invention relates to a solid beverage formula for reducing weight and inhibiting weight gain. The food formula mainly comprises resistant starch, medium chain triglyceride microcapsule powder, mulberry leaf extract, psyllium husk powder and other auxiliary food raw materials. The auxiliary food raw materials comprise one or a mixture of more of resistant dextrin, milk powder and fruit and vegetable powder. The formula comprises the following components in percentage by weight: 40%-80% of resistant starch, 2%-20% of medium chain triglyceride microcapsule powder, 2%-20% of psyllium husk powder, 0.5%-10% of mulberry leaf extract and 1%-20% of other auxiliary food raw materials. According to the solid beverage prepared by the formula, the food intake can be reduced by enhancing satiety; ketogenic heat consumption and fat gluconeogenesis are increased, and more fat is consumed; therefore, the purposes of reducing weight and inhibiting weight gain are achieved. According to the formula, on the basis of balancing diet, the goal of reducing weight to a certain degree can be achieved, and meanwhile, the health risk of traditional extremely-low carbon water ketone-producing diet is avoided. The formula is beneficial to regulating the balance of intestinal flora and improving glycometabolism and lipid metabolism. All ingredients in the formula are food raw materials.

This invention relates to the field of animal feed technology and discloses a compound nutritional feed suitable for the growth and development of Ili horses in high-altitude and cold regions. The feed comprises 88-92 parts roughage and 8-12 parts solid-dispersed microspheres. The solid-dispersed microspheres are made of hydrogenated palm oil, calcium propionate, anhydrous citric acid, and lysophosphatidylcholine, and have a lipid crystalline network structure. In an aqueous environment, the lysophosphatidylcholine within the microspheres establishes hydration channels, promoting water penetration and triggering an in-situ acid-base metathesis reaction between calcium propionate and anhydrous citric acid. The resulting liquid free propionic acid causes a sharp drop in the local melting point of the microspheres, leading to the disintegration of the macroscopic structure. This invention can simultaneously release free propionic acid and hydrogenated palm oil, providing energy through gluconeogenesis and intestinal enzymatic hydrolysis, respectively, achieving a dual-effect synergistic energy supply from carbohydrates and lipids. This meets the energy metabolism needs of Ili horses in high-altitude and cold environments and exhibits good long-term storage stability.

Use of glycerol monodecanoate in preparing a medicament for treating hyperglycemia or diabetes or a functional food for assisting in lowering blood glucose associated with hyperglycemia or diabetes. Glycerol monodecanoate reduces blood glucose by promoting the expression of the glucokinase gene and the insulin receptor gene in the liver glycolysis pathway and inhibiting the expression of the phosphoenolpyruvate carboxyl kinase gene and the glucose-6-phosphatase catalytic subunit gene in the gluconeogenesis pathway.

The invention discloses health-care tea for reducing blood sugar. The health-care tea is prepared from the following raw materials in parts by weight: 35-82 parts of gynostemma pentaphylla, 280-340 parts of dark green tea, 35-82 parts of astragalus membranaceus, 20-50 parts of herba epimedii, 5-14 parts of radix rehmanniae, 20-50 parts of corn stigma, 2-8 parts of liquorice and 7-22 parts of hawthorn. The traditional Chinese medicine composition is reasonable in compatibility, wide in raw material source and simple in preparation method, has an obvious effect of inhibiting gluconeogenesis, can also improve the content of liver glycogen, has the efficacy of reducing blood sugar, realizes regulation and recovery of human body balance, and achieves a stable and healthy state. The adopted traditional Chinese medicines are all natural medicinal materials, are safe and effective, and have no toxic or side effect.

The invention discloses double-stranded siRNA (small interfering Ribonucleic Acid) targeting liver Sam68 and application of the double-stranded siRNA in metabolic syndrome related diseases, and relates to the field of biological medicines. The double-stranded siRNA comprises a positive-sense strand and an antisense strand complementary to the positive-sense strand, the positive-sense strand is a modified or unmodified sequence of which the nucleotide sequence is shown as SEQ ID NO.41; the antisense strand is a modified or unmodified sequence of which the nucleotide sequence is as shown in SEQ ID NO. 42. The double-chain siRNA designed and synthesized on the basis of Sam68 can realize potent, dose-dependent and liver-limited Sam68 knock-down in vivo, inhibits liver gluconeogenesis by down-regulating glucagon signals, can reduce fasting blood-glucose, improve insulin sensitivity and protect diabetic liver from being damaged, and can be used for treating diabetic liver diseases such as diabetes mellitus, diabetes mellitus, diabetes mellitus, diabetes mellitus, diabetes mellitus and diabetes mellitus. A novel long-acting nucleic acid medicine is provided for diabetes, obesity, hypercholesterolemia, atherosclerosis and other metabolic syndrome related diseases.

To provide a composition having excellent blood sugar control capability.SOLUTION: In an aspect, a composition of the present invention including a complex component of Gallocatechin Gallate and Isoquercitrin can effectively inhibit gluconeogenesis in liver cells and effectively improve glucose transport in differentiated fat cells and liver cells, thereby exhibiting excellent blood sugar control efficacy.SELECTED DRAWING: Figure 1